长春瑞滨联合顺铂辅助化疗ⅢA期非小细胞肺癌的临床研究

摘要

ObjectiveTo compare the efficacy of adjuvant chemotherapy of vinorelbine plus carboplatin (NP) and vinorelbine plus cisplatin (NC) in patients with stage ⅢAnon-small cell lung cancer (NSCLC).Methods A total of 41 patients with ⅢA stage NSCLC in our in-patient department from January 2005 to January 2008 wereretrospectively analysed. Patients were divided intoNP and NCtreatment groups, followingwithradiotherapy. Patients in NP group received vinorelbine plus cisplatin, and patients in NC group received vinorelbine plus carboplatin. After that, all the clinical data, including responses, toxicity and survival rate were collected and analysed.ResultsThere were no significant difference between NP and NC groups in toxicity, total response rate and disease control rate (P>0.05). No death was reported. The 1 year- survival rate of NP group was higher than NC group (P<0.05). Conclusion There was no significant difference between the two groups in response rate, but NP therapy can improve 1 year- survival rate.%目的：比较长春瑞滨联合顺铂（NP）与长春瑞滨联合卡铂（NC）方案辅助化疗ⅢA期非小细胞肺癌（NSCLC）的临床疗效。方法回顾性分析2005年1月～2008年1月于我院住院治疗的41例临床诊断为ⅢA期NSCLC患者，共分为NP组和NC组，NP组(22例)使用长春瑞滨联合顺铂治疗，NC组（19例）使用长春瑞滨联合卡铂治疗。所有患者均接受放化疗结合治疗，回顾分析两组患者临床资料，并对疗效、不良反应及生存率评价，并进行统计分析。结果两组ⅢA期NSCLC患者治疗总有效率和疾病控制率差异无统计学意义（P＞0.05），无死亡病例，毒副反应发生率差异无统计学意义（P＞0.05），1年生存率NP组较高，差异具有统计学意义（P＜0.05）。结论 NP与NC化疗方案在提高ⅢA期治疗有效率上无显著差异，但NP可显著提高患者1年生存率。